Skip to content

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Moderna Q1 earnings: will the vaccine maker maintain its growth beyond the COVID-19 pandemic?

Moderna is expected to report earnings on 04 May before the market opens. Investors are keen to see if Moderna can maintain its exponential profit growth since 2021 or if any new opportunities will open up for the company?

Source: Bloomberg

When is the report date?

Moderna Inc is expected to report earnings on 04 May before the market opens. The report will be for the fiscal Quarter.

What to expect?

According to Zacks Investment Research, the consensus EPS forecast for the quarter is $5.18 per share on revenue of $4.62 billion. The reported EPS for the same quarter last year was $2.84.

Source: Moderna

Investors are keen to see if Moderna can maintain its recent exponential profit growth since 2021 or if any new opportunity may open up for the company. Given that most of the world has entered into a post-pandemic phase, the natural assumption is that room for growth will be limited.

However, the company has shown great confidence in a recent speech that COVID-19 is moving towards an endemic phase that will require the continuous use of vaccines for the foreseeable future.

Moderna projects roughly $22 billion in Spikevax sales this year, along with strong commitments for 2023. The company’s product pipeline, which uses its messenger RNA (mRNA) technology, has planned for the distribution of new drugs for the influenza and HIV vaccine.

Moreover, last week Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec to support a long-term strategic partnership with the Government of Canada. Based on the above, there is good reason to believe that Moderna’s growth is sustainable beyond the COVID-19 pandemic.

Moderna’s product pipeline

Source: Moderna

Nonetheless, the short-term outlook for the business is still cloudy. The high degree of uncertainty in the economy with the multiple interest rate rises fast approaching, has cast a shadow on the growth stocks. The share price for Moderna has dropped by nearly 60% year-to-date and it’s now traded at approximately 4.75* PE ratio—the lowest compared to its peers, but with the highest EPS.

Technical Analysis

The past six months have seen the value of Moderna evaporate by over 70% as the pandemic cools. Current support might come from a Mach low at 126. On the topside, imminent resistance sits at the level connecting 20- and 50-days MA at the moment. From a mid-term perspective, the band in between $126 to $169 looks like to be the possible range for the price to move.

The current momentum shown from the RSI may signal that a near-term bearish momentum could unfold, although the trend line from the weekly chart will place a massive challenge for the stock to rebound.

Source: TradingView
Source: TradingView

This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Start trading forex today

Trade the largest and most volatile financial market in the world.

  • Spreads start at just 0.6 points on EUR/USD
  • Analyse market movements with our essential selection of charts
  • Speculate from a range of platforms, including on mobile

Find out more

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

<h3>How much does trading cost?</h3>
<h3>Find out about IG</h3>
<h3>Plan your trading</h3>

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.